Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population

Pediatric Allergy and Immunology

Volumn 15, Issue 6, 2004, Pages 551-557

  Abelson, Mark B ^a,b,d   Ferzola, Nancy J ^c   McWhirter, Cecilia L ^c   Crampton, Henry J ^b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b Ophthalmic Research Associates   (United States)

^c Novartis Ophthalmics Inc   (United States)

^d NONE   (United States)

Author keywords

Allergen challenge; Allergic conjunctivitis; Clinical trial; Ketotifen fumarate; Pediatric

Indexed keywords

ALLERGEN; EYE DROPS; KETOTIFEN FUMARATE; PLACEBO;

ADOLESCENT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DAILY LIFE ACTIVITY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EYELID EDEMA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OCULAR PRURITUS; PAIN; PEDIATRICS; PHARYNGITIS; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SCORING SYSTEM; SINGLE DRUG DOSE; SKIN DISEASE; STATISTICAL SIGNIFICANCE; VISUAL IMPAIRMENT;

ADOLESCENT; ANTI-ALLERGIC AGENTS; CHILD; CONJUNCTIVITIS, ALLERGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETOTIFEN; MALE; OPHTHALMIC SOLUTIONS; PRURITUS; TEARS; TIME FACTORS; TREATMENT OUTCOME;

EID: 11144337172     PISSN: 09056157     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2004.00146.x     Document Type: Article

References (16)

1. SIMONS FER. Learning impairment in allergic rhinitis. Allergy Asthma Proc 1996: 17: 185-9.
2. NATHAN RA, MELTZER EO, SELNER JC, STORMS W. Prevalence of allergic rhinitis in the United States. J. Allergy Clin Immunol 1997: 99: S808-S814.
3. ABELSON MB, GEORGE MA, GAROFALO C. Differential diagnosis of ocular allergic disorders. Ann Allergy 1993: 70: 95-109.
4. BIELORY L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002: 3: 541-53.
5. MELTZER EO. Treatment options for the child with allergic rhinitis. Clin Pediatr 1998: 37: 1-10.
6. MELTZER EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001: 108 (Suppl. 1): S45-S53.
7. JUNIPER EF, GUYATT GH, DOLOVICH J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994: 93: 413-23.
8. FIREMAN P. Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol 2000: 105: S616-S621.
9. SIMONS FE. H1 Antihistamines in children. Clin Allergy Immunol 2002: 17: 437-64.
10. QIDWAI JC, WATSON GS, WEILE JM. Sedation, cognition, and antihistamines. Curr Allergy Asthma Rep 2002: 2: 216-22.
11. VUURMAN EF, VAN VEGGEL LM, UITERWIJK MM, et al. Seasonal allergic rhinitis and antihistamine effects on children. Ann Allergy 1993: 71: 121-6.
12. GRANT SM, GOA KL, FITTON A, SORKIN EM. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990: 40: 412-48.
13. ABELSON MB, CHAPIN MJ, KAPIK BM, SHAMS N. Ocular tolerability and safety of ketotifen fumarate ophthalmic solution. Adv Therapy 2002: 19: 161-9.
14. ABELSON MB, CHAMBERS WA, SMITH LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990: 108: 84-8.
15. TAUER CA. Testing drugs in pediatric populations: the FDA mandate. Account Res 1999: 7: 37-58.
16. MOLLER C, BJORKSTEN B, NILSSON G, DREBORG S. The precision of the conjunctival provocation test. Allergy 1984: 39: 37-41.